These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31806969)

  • 1. Erratum: Delivery Of miR-375 And Doxorubicin By Lipid-Coated Hollow Mesoporous Silica Nanoparticles To Overcome Multiple Drug Resistance In Hepatocellular Carcinoma [Corrigendum].
    Int J Nanomedicine; 2019; 14():8753-8754. PubMed ID: 31806969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
    Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum: Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum].
    Int J Nanomedicine; 2021; 16():7859-7860. PubMed ID: 34880611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum: Development of an Oral Push-Pull Osmotic Pump of Fenofibrate-Loaded Mesoporous Silica Nanoparticles [Corrigendum].
    Int J Nanomedicine; 2022; 17():15-16. PubMed ID: 35023916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum: miR-221 Suppression Through Nanoparticle-Based miRNA Delivery System for Hepatocellular Carcinoma Therapy and Its Diagnosis as a Potential Biomarker [Corrigendum].
    Int J Nanomedicine; 2020; 15():8293-8294. PubMed ID: 33149576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erratum: Doxorubicin-Loaded Poly (Lactic-Co-Glycolic Acid) Nanoparticles Coated with Chitosan/Alginate by Layer by Layer Technology for Antitumor Applications [Corrigendum].
    Int J Nanomedicine; 2021; 16():4187. PubMed ID: 34177263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum: Lipid-Polymer Hybrid Nanoparticles for Controlled Delivery of Hydrophilic and Lipophilic Doxorubicin for Breast Cancer Therapy [Erratum].
    Int J Nanomedicine; 2020; 15():839. PubMed ID: 32103940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum: GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma [Corrigendum].
    Int J Nanomedicine; 2022; 17():3073-3074. PubMed ID: 35855749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-coated hollow mesoporous silica nanospheres for co-delivery of doxorubicin and paclitaxel: Preparation, sustained release, cellular uptake and pharmacokinetics.
    Qiu Y; Wu C; Jiang J; Hao Y; Zhao Y; Xu J; Yu T; Ji P
    Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():835-843. PubMed ID: 27987779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
    Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
    Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum: Targeted Delivery of Doxorubicin Utilizing Chitosan Nanoparticles Surface Functionalized with Anti Her2 Trastuzumab [Corrigendum].
    Int J Nanomedicine; 2022; 17():5047-5048. PubMed ID: 36303805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-MnO
    Fang J; Wang Q; Yang G; Xiao X; Li L; Yu T
    Colloids Surf B Biointerfaces; 2019 Jul; 179():250-259. PubMed ID: 30978612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum: Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum].
    Int J Nanomedicine; 2019; 14():7919. PubMed ID: 31632008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum: A Reliable Approach for Assessing Size-Dependent Effects of Silica Nanoparticles on Cellular Internalization Behavior and Cytotoxic Mechanisms [Corrigendum].
    Int J Nanomedicine; 2020; 15():10169. PubMed ID: 33363372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erratum: Hyperthermia Mediated by Dextran-Coated La
    Int J Nanomedicine; 2022; 17():1481-1482. PubMed ID: 35378878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hollow Mesoporous Silica Nanoparticles with Tunable Structures for Controlled Drug Delivery.
    Li Y; Li N; Pan W; Yu Z; Yang L; Tang B
    ACS Appl Mater Interfaces; 2017 Jan; 9(3):2123-2129. PubMed ID: 28004570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles.
    Kang MS; Singh RK; Kim TH; Kim JH; Patel KD; Kim HW
    Acta Biomater; 2017 Jun; 55():466-480. PubMed ID: 28373086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antitumor efficacy of irinotecan-loaded galactosyl modified lipid bilayer-coated mesoporous silica nanoparticles against hepatocellular carcinoma cells].
    Chen X; Zhang XX; Li FF; Zhao YN; Jia Z; Gan Y; Li J
    Yao Xue Xue Bao; 2014 May; 49(5):718-25. PubMed ID: 25151746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional PEG modified DOX loaded mesoporous silica nanoparticle@CuS nanohybrids as photo-thermal agent and thermal-triggered drug release vehicle for hepatocellular carcinoma treatment.
    Wu L; Wu M; Zeng Y; Zhang D; Zheng A; Liu X; Liu J
    Nanotechnology; 2015 Jan; 26(2):025102. PubMed ID: 25517859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.